Radiopharmaceuticals in cardiology

Renata Mikołajczak, Piotr Garnuszek
National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, Poland

[Received 16 I 2012; Accepted 31 I 2012]

Abstract

Myocardial perfusion studies are among the most often performed investigations in Nuclear Medicine. However, the development of radiopharmaceuticals for cardiology is an emerging discipline and several other radiotracers have been proven to be useful. Although the myocardial perfusion studies have a well-established role in the management of cardiac disorders, still a number of radiopharmaceuticals are under development for a variety of specific cardiac indications and their eventual clinical role remains to be seen. The paper provides a short overview of currently used radiopharmaceuticals and potential molecular imaging radiotracers applicable in cardiology.

Key words: nuclear medicine, nuclear cardiology, cardiac imaging radiopharmaceuticals, status and trends

Introduction

Myocardial perfusion studies are among the most often performed investigations in Nuclear Medicine. That high number of studies is facilitated by the availability of suitable tracers radiolabelled with $^{99m}$Tc. Hence, the technetium agents were used for more than 90% of the 8 million cardiac imaging studies in the US in 2006 [1] out of a total of over 20 million nuclear medicine procedures. The number of cardiac imaging studies performed in Europe is generally lower than in US and it is varying between European countries. In Poland utilization of the nuclear cardiology procedures performed in 2008 accounted for little over 11 per cent of the total number of nuclear medicine procedures [2]. However, the development of radiopharmaceuticals for cardiology is an emerging discipline and several other radiotracers have been proved to be useful. The aim of this paper is to provide the brief overview of the radiopharmaceuticals available today and also on the tracers which are entering the field.

Myocardial perfusion

Myocardial perfusion imaging is a well established noninvasive method of assessing coronary blood flow. It is capable of identifying regional abnormalities in coronary artery blood flow and determining their physiological relevance to myocardial function and viability. Used frequently in conjunction with either physical exercise or pharmacological stress, the myocardial perfusion imaging is useful in unmasking myocardial perfusion deficits not evident at rest [3].

Among the earliest developed radiopharmaceuticals used in cardiology there were tracers for measurement of myocardial blood flow [4]. The first radioactive tracer used to assess perfusion was potassium-43, because of its avid extraction and retention. Since the 1970’s, thallium-201 ($^{201}$Tl, $t_{1/2}$=73 h) has been used extensively as myocardial perfusion agent for assessing myocardial viability [5]. The uptake of these tracers occurs predominantly through the Na+/K+ channel. For $^{201}$Tl, the rapid myocardial extraction depends on perfusion, whereas the myocardial retention/redistribution reflects myocardial viability. In the 1980’s, lipophilic technetium-99m complexes were demonstrated as good myocardial perfusion agents [6]. Currently, sestamibi [7] and tetrofosmin [8] are approved agents by FDA, sestamibi is also approved in EU.

Recently a number of generic sestamibi kits have been granted marketing authorization. The most frequently used SPECT and PET tracers for assessing myocardial blood flow are presented in Table 1. Their more detailed characteristics is given below.

SPECT perfusion tracers

Thallous ($^{201}$Tl) chloride injection

USP [10], Ph. Eur. [11] (monograph 0571). $^{201}$Tl is a cyclotron produced radionuclide with the half-life of 73 hours. For many years, planar imaging and SPECT with thallium-201 chloride constituted the only scintigraphic technique available for detecting coronary artery disease and assessing prognosis in patients undergoing stress perfusion imaging [12]. The chemical properties of this monovalent cation result that it acts similarly to potassium and is taken into viable cardiac myocytes. It distributes in cardiac tissue roughly in proportion to regional blood flow. In practice, it is injected when the patient is at peak exercise or shortly after the pharmacological stress agent is administered. Defects on the initial image can represent regional ischemia or nonviable myocardium. As the cardiac stress is discontinued, the thallium-201 redistributes and...
fills in areas that were underperfused due to ischemia (reversible defect). Regions of the heart that have been irreversibly damaged by previous myocardial infarction do not demonstrate resolution of the defect on the delayed image (fixed defect). In this way, the test can discriminate the regions of inducible ischemia at risk for future myocardial infarction and areas that have been already irreversibly damaged by prior myocardial infarction. Thallium-201 has several virtues as a myocardial perfusion agent [13]. It is characterized by regional blood clearance half-time of < 30 s and a first pass extraction in the myocardium of > 88%, while 99mTc-sestamibi blood clearance half-time is > 1 min and a first pass extraction in the myocardium is 50% to 60%. These biological characteristics of thallium provide higher contrast between regions of normal perfusion and zones of ischemia, even on planar myocardial perfusion studies (see Table 1). Some physical and biological characteristics of thallium, however, are not so favorable. The electron capture decay of 201Tl produces 88 X-ray photons at 70 to 80 keV and approximately 12 gamma photons at 135 and 167 keV for each disintegration. In addition to the low energy of the predominant photon, the physical half-life of 73 h and biological half-life of approximately 10 days (240 h) results in a relatively long effective half-life of approximately 56 h. These biological characteristics of thallium provide higher contrast between regions of normal perfusion and zones of ischemia, even on planar myocardial perfusion studies (see Table 1). Some physical and biological characteristics of thallium, however, are not so favorable. The electron capture decay of 201Tl produces 88 X-ray photons at 70 to 80 keV and approximately 12 gamma photons at 135 and 167 keV for each disintegration. In addition to the low energy of the predominant photon, the physical half-life of 73 h and biological half-life of approximately 10 days (240 h) results in a relatively long effective half-life of approximately 56 h. In addition to myocardium, skeletal muscle and liver, the tracer also localizes in the testes and kidneys, producing an effective dose equivalent to 34.5 mSv/150 MBq. Due to relatively high absorbed dose the administered radioactivity of 201Tl is usually limited to well below 150 MBq, which in turn may limit the image quality.

**Technetium (99mTc) sestamibi injection**

USP [10], Ph. Eur. [11] (monograph 1926). 99mTc-sestamibi (99mTc-MIBI; Fig. 1) is a cationic, lipophilic complex that consists of 1 atom of 99mTc in a 1+ oxidation state and 6 molecules of 2-methoxyisobutylisonitrile (MIBI).

Sestamibi contains isonitrile groups that form a complex with 99mTc after reduction with stannous ions. Since isonitriles are volatile and unstable compounds, MIBI is available in stabilized form as copper tetrafluoroborate adduct, [Cu(MIBI)_3]BF_4, which should be decomposed during radiolabelling carried out at elevated temperature. Lyophilized Sestamibi kits (Cardiolite, 99mTc-MIBI kit, CardioTop, Technescan Sestamibi, etc.) contain a mixture of [tetrakis(2-methoxy-2-methylpropyl-1-isocyanide)copper (1+)] tetrafluoroborate as the active substance, and excipients like: stannous chloride (reductant), L-cysteine hydrochloride (ancillary reductant), sodium citrate (buffering substance), and mannitol (bulking agent). Radiolabelling is carried out by adding a sufficient amount of sterile, non-pyrogenic, oxidant-free sodium pertechnetate (99mTc) eluate from the 99Mo/99mTc generator to the kit vial and heating the mixture in a boiling water bath for 10 min. The potential radiochemical impurities present in 99mTc-sestamibi preparation that can affect image quality are: pertechnetate (99mTc) ion, technetium-99m in colloidal form, and 99mTc-pentamibi dimethylvinyl isonitrile ([(OC-6-11)hexakis[1-(isocyano-kC)-2-methoxy-2-methylpropane] [99mTc]technetium(I) chloride]).

![Figure 1. Structure of 99mTc-sestamibi (OC-6-11)-hexakis[1-(isocyano-kC)-2-methoxy-2-methylpropane] [99mTc]technetium(I) chloride).](image)

| Table 1. Comparison of the main blood flow tracers. Table derived from [9] |
|---------------------------------|-----------------|-----------------|-----------------|
| **Tracer**                      | **Physical half-life** | **Myocardial extraction (%)** | **Clearance half-life** | **Viability** |
| SPECT                           |                 |                 |                 |             |
| Thallium-201                    | 73 h            | 85              | Slow            | ++ +         |
| 99mTc-sestamibi                 | 6 h             | 65              | Very slow       | ++           |
| 99mTc-tetrofosmin               | 6 h             | 60              | Very slow       | ++           |
| PET                             |                 |                 |                 |             |
| Rubidium-82                     | 76 s            | 65              | Slow            | ++           |
| 13N-ammonia                     | 10 min          | 80              | Very slow       | +            |
| 15O-water                       | 2 min           | 100             | Fast            | ++           |
| PET                             |                 |                 |                 |             |
| Rubidium-82                     | 76 s            | 65              | Slow            | ++           |
| 13N-ammonia                     | 10 min          | 80              | Very slow       | +            |
| 15O-water                       | 2 min           | 100             | Fast            | ++           |

*Extraction is flow dependent; values given represent estimates at resting flow rates.*
Technetium (99mTc) tetrofosmin injection

USP [10]. 99mTc-tetrofosmin is a cationic complex of technetium-99m at the oxidation state 5+ and two molecules of tetrofosmin ([6,9-bis(2-ethoxyethyl)-3,12-dioxo-6,9-diphosphatetradecane] (Fig. 2). The chemical formula of the 99mTc-complex is [99mTc(tetrofosmin)],O$_2$ with a charge of 1+. 99mTc-tetrofosmin is a diagnostic radiopharmaceutical used in nuclear medicine cardiac imaging [8]. It is commercially available as lyophilized kit under the brand name Myoview (GE Healthcare). The Myoview kit contains a lyophilised mixture of 0.23 mg of tetrofosmin as the active substance and excipients: D-gluconate, and sodium hydrogen carbonate. Radiolabelling 0.23 mg of tetrofosmin as the active substance and excipients: D-gluconate, and sodium hydrogen carbonate. Radiolabelling is carried out by adding sodium pertechnetate [99mTc] eluate from the 99Mo/99mTc generator to the kit vial and incubating the mixture for 15 min at room temperature. 99mTc-glucenate is initially formed with reduced 99mTc, which is obtained by stannous ion reduction, and then ligand exchange between 99mTc-glucenate and the tetrofosmin group gives 99mTc-tetrofosmin. The radiochemical purity of 99mTc-tetrofosmin should not be less than 90% of the total radioactivity [15].

Uptake of 99mTc-tetrofosmin in the myocardium and in tumours and metastases is similar to that of 99mTc-MIBI [16]. The myocardial uptake of 99mTc-tetrofosmin appears to occur by a passive diffusion process (no redistribution). Intravenously administered, it is rapidly taken up by myocardial tissue and reaches its maximum level in approximately 5 minutes. 66% of the total injected dose is excreted within 48 hours after injection (40% urine, 26% feces). 99mTc-tetrofosmin is indicated for use in scintigraphic imaging of the myocardium under stress and rest conditions. It is used to determine areas of reversible ischemia and infarcted tissue in the heart. It is also indicated to detect changes in perfusion induced by pharmacologic stress (adenosine) in patients with coronary artery disease. When injected at stress, 99mTc-tetrofosmin accumulates in viable myocardial tissue in relation to myocardial blood flow; thus, ischemic areas (e.g., those supplied by stenotic vessels) are detectable as areas of less accumulation. Its third indication is to assess left ventricular function (ejection fraction) in patients thought to have heart disease.

PET perfusion tracers

Several positron-emitting radionuclides are also utilized to obtain tomographic images of regional myocardial perfusion (see Table 1), metabolism and the receptor density [17]. Four different approaches have been utilized for assessment of myocardial viability: (1) perfusion-FDG metabolism imaging, (2) determination of oxidative metabolism with 11C-acetate, (3) uptake and retention of 82Rb and (4) the water perfusable tissue index [5]. These PET tracers not only allow for the diagnosis of coronary artery disease with a high degree of sensitivity and specificity, but using mathematical models also allow quantitative assessment of myocardial perfusion.

Rubidium (82Rb) chloride injection

USP [10]. Rubidium-82 chloride has been introduced as tracer for myocardial imaging in consequence of searching for positron-emitting analogue of 201Tl with improved physical characteristics. 82Rb has a half-life of 76 s and maximum $\beta^+$ energy of 3.3 MeV. It is obtained by decay of parent radionuclide 82Sr from a generator system with hydrous stannic oxide column. Strontium-82 decays to 82Rb with a half-life of 25 days (600 hrs), hence the useful life of a generator is about 1 month. Because of the short half-life of the daughter radionuclide, the generator can be eluted at 10 min intervals with high yield. The generator is eluted with saline and eluate is infused directly to the patient as 82Rb chloride in saline. Today the 82Sr/82Rb generators are offered by Bracco Diagnostic Inc (US) as CardioGen-82 (Rubidium Rb 82 Generator) [18]. The design and validation of an in-house generator has been also published [19].

Gould et al. [20] showed that 82Rb is a short-lived tracer useful for myocardial perfusion imaging. 82Rb is a cation, with an intracellular uptake across the cellular membrane that reflects active transport. It behaves as an analogue of potassium and is taken up into the heart actively by Na$^+$/K$^+$.ATPase pump. It is rapidly cleared from the blood and taken up to a variable degree by all tissues and organs except brain. The short half-life of 82Rb permits the entire rest/stress protocol to be completed within 45 minutes, which is very convenient for the patient. 82Rb has favorable physiologic and physical properties, however it is a difficult tracer to image. It emits an unusually high-energy positron, which can travel a con-
siderable distance in tissue before annihilating, thereby affecting global image quality [21].

**Ammonia (13N) injection**

USP [10], Ph. Eur. [11] (monograph 1492). 13N has a half-life of 10 minutes and maximum β+ energy 1.2 MeV (must be obtained from an on-site cyclotron). It is prepared by proton irradiation of water target in cyclotron followed by reduction, distillation and trapping in a slightly acidic solution. Ammonia equilibrates with ammonium ion in the blood stream. It is the neutral ammonia species, which diffuses across biological membranes into cells and is enzymatically converted into glutamine. First pass extraction is 80% at normal flow but falls off at high flow rates. It is rapidly cleared from circulation and extracted by liver (15%), lungs, myocardium (2-4%), brain, kidney and bladder. Initial uptake in the lungs clears rapidly allowing visualization of the heart. A complete rest/stress protocol requires about 2 hours to allow for decay of 13N between studies. Using 13N-ammonia the absolute quantification of myocardial perfusion can be performed [17].

**Water (15O) injection**

USP [10], Ph. Eur. [11] (monograph 1582). 15O-water is widely used for measurement of regional cerebral perfusion, but can also be used in the heart. O-15 has a half-life of 2 minutes and maximum β+ energy 1.7 MeV (must be obtained from the on-site cyclotron, formed in the reaction of molecular oxygen with small amount of hydrogen). It diffuses freely across membranes and enters total body water space. Delivery of 15O-water to myocardial (and other) cells is efficient but rapid washout occurs, which necessitates dynamic imaging or subtraction of blood pool activity. The short half-life allows a conveniently short rest/stress imaging protocol but can result in poor counting statistics. Absolute quantification can be performed [17].

**Myocardial oxygen consumption**

**Sodium acetate (1-11C) injection**

USP [10], Ph. Eur. [11] (monograph 1920). 11C-acetate is a tracer of citric acid cycle and thus directly of oxidative metabolism, allowing assessing myocardial oxygen consumption and predicting viability. 11C has a half-life of 20.4 min and maximum β+ energy 0.96 MeV. It is obtained from an on-site cyclotron by proton irradiation of water target in cyclotron followed by reduction, distillation and trapping in a slightly acidic solution. Ammonia equilibrates with ammonium ion in the blood stream. It is the neutral ammonia species, which diffuses across biological membranes into cells and is enzymatically converted into glutamine. First pass extraction is 80% at normal flow but falls off at high flow rates. It is rapidly cleared from circulation and extracted by liver (15%), lungs, myocardium (2-4%), brain, kidney and bladder. Initial uptake in the lungs clears rapidly allowing visualization of the heart. A complete rest/stress protocol requires about 2 hours to allow for decay of 13N between studies. Using 13N-ammonia the absolute quantification of myocardial perfusion can be performed [17].

**Hypoxia**

Abnormalities in tissue oxygenation underlie many of the metabolic and contractile changes that occur in ischemic myocardium. As mentioned above, 11C-acetate can be used to indirectly assess myocardial oxygen consumption. The use of 15O is a more direct way to image myocardial oxygen consumption, but its use is quite complicated and limited to the centers with cyclotrons. Most of the tracers for imaging hypoxia that were developed so far are nitroimidazole based [22]. Nitroimidazoles are a class of lipophilic compounds with high electron affinity that have been developed as radiosensitizers of hypoxic regions in tumors [23]. These compounds readily diffuse through the cells. The nitro group can be chemically reduced to form a radical, which under normal oxygen content will react to regenerate the parent compound and diffuse out of the cell. Under hypoxic conditions, the nitro radical can interact with intracellular macromolecules and are trapped. Hypoxia tracers such as 18F-fluoromisonidazole (18F-MISO) and 62/64Cu-ATSM are selectively trapped in hypoxic tissue by a bioreductive mechanism and result in hot spot images [24].

**18F Fluoromisonidazole**

18F-fluoromisonidazole (18F-MISO; Fig. 3) can be easily radio-labelled by reacting 2-nitroimidazole with 18F-labeled epifluorohydroxymethyl or by fluorination of O-THP protected tosylate of misonidazole followed by acidic deprotection.

**62/64Cu-ATSM**

64Cu-ATSM is a promising agent for the imaging of hypoxic tissues. Copper-64 (T1/2=12.7 hours; β+, 0.653 MeV (17.8 %); β-, 0.579 MeV (38.4 %)) has decay characteristics that allow for positron emission tomography (PET) imaging and targeted radiotherapy of cancer. With a high membrane permeability and redox potential, a lipophilic 64Cu-ATSM conjugate is preferentially taken up by hypoxic cells compared to normoxic cells [25], the extent of retention in tissue is inversely related to the state of tissue oxygenation allowing the quantification of tissue hypoxia by

---

**Figure 3. [18F]Fluoromisonidazole (1-([18F]fluoro-3-(2-nitro-imidazol-1-yl)-propan-2-ol)**

**Figure 4. Structure of 64Cu-ATSM (64Cu(II)-diacetyl-bis(N'-methylthiosemicarbazone)**
 positron emission tomography (PET). In addition, the radioactive copper moiety of this agent may deliver a selective cytotoxic dose of beta radiation to hypoxic tumor cells.

**Myocardial glucose metabolism**

Fludeoxyglucose (18F injection)

USP [10], Ph. Eur. [11] (monograph 1325). 2-Deoxy-2-[18F]fluoroglucose (18F-FDG; Fig. 5) with the half-life of 18F of 110 min has been used for measuring glucose metabolism in humans. It is commonly produced by nucleophilic substitution reaction of a O-acetyl-protected mannose triflate with [18F]fluoride (resolubilized in acetonitrile in the presence of K₂CO₃ and Kryptofix 222) followed by acid hydrolysis. The final tracer is purified using a mixed cation-anion exchange column [26].

Under physiological, fasting circumstances, the heart depends on the breakdown of long-chain fatty acids for energy needed for contraction. However, after a carbohydrate meal or with myocardial ischemia, the pattern of substrate switches to glucose. FDG is a glucose analog with a metabolic pattern different from native glucose. FDG is initially extracted at a rate different than glucose. 18F-FDG is rapidly cleared from circulation with the half-time < 1 min. Three phases can be identified with half-lives of 0.2–0.3 min, 10–13 min and 80–95 min. About 30% is excreted via kidneys. Tissues of highest retention are the heart and brain. Following myocardial uptake, FDG is phosphorylated to FDG-6-phosphate and is then trapped in the myocardium because unlike phosphorylated glucose, it is a poor substrate for glycogen synthesis, the fructose phosphate shunt and glycolysis. Regional myocardial uptake of FDG therefore reflects relative distribution of regional rates of exogenous glucose utilization [4, 5].

Radiotracers for myocardial sympathetic nerve imaging

Regional and global abnormalities of cardiac sympathetic nervous function are involved in various clinical disorders, such as myocardial infarction, hypertrophic cardiomyopathy and congestive heart failure. The major neurotransmitter of the sympathetic nervous system is norepinephrine, which is taken up by the transporter from circulation and stored in neuronal vesicles by vesicular monoamine transporter. Several radiolabelled analogs of norepinephrine have been developed, including PET tracers such as radiolabelled catecholamine analogues: 6-[18F]fluorodopa-, (-)-6-[18F]fluoroepinephrine, and (-)-131C-epinephrine and catecholamine analogues such as 11C-meta-hydroxyephedrine, 11C-fluorometaraminol and 11C-phenylephrine [4, 17]. However, the most widely used tracer is 123I-labelled meta-iodobenzylyguanidine (123I-MIBG) [27].

Iobenguane (123I) injection

USP [10], Ph. Eur. [11] (monograph 1113). 1-(3-[123I]iodobenzyl)guanidine (123I-MIBG, 123I-Iobenguane; Figure 6) shares the cellular transport and storage mechanism with norepinephrine. Both enter the neuronal cells and are stored in chromaffin granules and secreted in response to acetylcholine. 123I-MIBG is rapidly taken up by sympathetic nerves. A profound loss of 123I-MIBG uptake is observed in affected myocardium, similar loss of uptake was observed in patients with heart transplants [4].

**Future trends**

Radionuclide imaging of angiogenesis

Angiogenesis is defined as the process of sprouting new capillaries from preexisting microvessels. The main targets of imaging have been αvβ3 integrin and vascular endothelial growth factor (VEGF). Arginine-glycine-aspartate (RGD) is a peptide sequence that binds integrin, and the derivatives labeled with 18F [28, 29] and 64Cu [30] have been evaluated in patients with cancer. An antibody which binds to VEGF has been labeled with 124I [31].

64Cu-6DOTA-VEGF121 — a PET tracer has been also developed for imaging angiogenesis [32].

Radionuclide imaging in apoptosis and necrosis

Apoptosis is an indicator of variety of conditions within the heart, including ischemia/reperfusion injury, autoimmune myocarditis, areas at risk following acute myocardial infarction, and in transplant rejection. The protein annexin V, which binds to phosphatidyl choline externalized by cells undergoing apoptosis, has been labeled with 99mTc for SPECT [33, 34]. 99mTc-labelled annexin V was subsequently utilized in humans to detect in vivo cell death in patients presenting with myocardial infarction. Regional retention of 99mTc-labelled annexin V correlated with the perfusion defect identified 6-8 weeks after discharge, providing a proof of concept that annexin-V imaging can be utilized for noninvasive detection of myocardial cell death. Annexin V has been labeled with 18F [35], 124I [36] and 68Ga [37] for PET imaging. Recently, the first-in-humans study with 18F-labelled 2-(5-fluoropentyl)-2-methyl malonic acid (18F-ML-10), a small-molecule PET tracer for apoptosis, has been also reported [38].

Figure 5. Structure of 18F-FDG (2-[18F]fluoro-2-deoxy-D-glucose)

Figure 6. Structure of 123I-MIBG (1-(3-[123I]iodobenzylyguanidine)
Although the myocardial perfusion studies have a well-established role in the management of cardiac disorders, still the numbers of radiopharmaceuticals are under development for a variety of specific cardiac indications and their eventual clinical role remains to be seen. Table 2 provides the summary of cardiac imaging tracers in use and also at advanced stage of development, including their physical half-life, photon energy and possible applications in cardiac imaging.

Molecular imaging is a new and evolving field that employs a targeted approach to noninvasively assess biologic processes in vivo [39]. Some of the receptor targeting tracers have been described in this review. Other myocardial receptors are explored as potential targets for radionuclide imaging, such as α- and β-adrenergic receptors, muscarinic or benzodiazepine receptors. A noninvasive imaging technique to assess the receptor density and drugs binding to these receptors would provide new insights into the etiology of myocardial disease.

### References


### Table 2. Summary of cardiac imaging tracers

<table>
<thead>
<tr>
<th>Tracer</th>
<th>Physical half-life</th>
<th>Photon energy (keV)</th>
<th>Imaging technique</th>
<th>Application / Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thallous-201 chloride</td>
<td>72.912 h</td>
<td>X: 10, 69-71, 80γ: 135, 167</td>
<td>SPECT</td>
<td>Myocardial perfusion</td>
</tr>
<tr>
<td>99mTc-sestamibi</td>
<td>6.01 h</td>
<td>X: 18-21γ: 141</td>
<td>SPECT</td>
<td>Myocardial perfusion, tumor imaging</td>
</tr>
<tr>
<td>99mTc-tetrofosmin</td>
<td>6.01 h</td>
<td>X: 18-21γ: 141</td>
<td>SPECT</td>
<td>Myocardial perfusion</td>
</tr>
<tr>
<td>Rubidium-82 chloride</td>
<td>76 s</td>
<td>γ: 511</td>
<td>PET</td>
<td>Myocardial perfusion</td>
</tr>
<tr>
<td>13N-ammonia</td>
<td>9.965 min</td>
<td>γ: 511</td>
<td>PET</td>
<td>Myocardial perfusion</td>
</tr>
<tr>
<td>18O-water</td>
<td>122.24 s</td>
<td>γ: 511</td>
<td>PET</td>
<td>Myocardial perfusion</td>
</tr>
<tr>
<td>18F-FDG</td>
<td>109.77 min</td>
<td>γ: 511</td>
<td>PET</td>
<td>Imaging of metabolism — myocardial tissue viability, myocardial perfusion</td>
</tr>
<tr>
<td>13C-acetate</td>
<td>20.385 min</td>
<td>γ: 511</td>
<td>PET</td>
<td>Imaging of metabolism — oxygen consumption, hypoxia</td>
</tr>
<tr>
<td>18F-MISO</td>
<td>109.77 min</td>
<td>γ: 511</td>
<td>PET</td>
<td>Hypoxia</td>
</tr>
<tr>
<td>64Cu-ATSM</td>
<td>12.7 h</td>
<td>γ: 511, 1350</td>
<td>PET</td>
<td>Hypoxia</td>
</tr>
<tr>
<td>123I-MIBG</td>
<td>13.27 h</td>
<td>X: 4, 27-31γ: 159</td>
<td>SPECT</td>
<td>Myocardial sympathetic nerve imaging</td>
</tr>
<tr>
<td>64Cu-6DOTA-VEGF        12.7</td>
<td>h γ: 511, 1350</td>
<td>PET</td>
<td>Angiogenesis</td>
<td></td>
</tr>
<tr>
<td>99mTc-HYNIC-annexin V</td>
<td>6.01 h</td>
<td>X: 18-21γ: 141</td>
<td>SPECT</td>
<td>Apoptosis</td>
</tr>
<tr>
<td>68Ga-annexin V</td>
<td>67.629 min</td>
<td>X: 9-10γ: 511, 1.077</td>
<td>PET</td>
<td>Apoptosis</td>
</tr>
</tbody>
</table>


